Davidson 2003.

Methods	6‐week dietary run‐in washout period 6‐week before and after trial
Participants	838 men and women aged > 20 years with primary hypercholesterolaemia 337 received fluvastatin triglycerides ≤ 4.5 mmol/L (399 mg/dL) LDL‐C ≥ 3.4 mmol/L (131mg/dL) with evidence of CHD or other atherosclerotic disease LDL‐C ≥ 4.1 mmol/L (159mg/dL) with ≥2 other CHD risk factors but no CHD or other atherosclerotic disease LDL‐C ≥ 4.9 mmol/L (189mg/dL) without CHD or other atherosclerotic disease and < 2 other CHD risk factors exclusion criteria: MI, coronary bypass surgery or angioplasty in the prior 3 months current coronary insufficiency, clinically significant ventricular arrhythmias, potential childbearing, pregnancy Fluvastatin 20 mg/day baseline TC : 7.1 mmol/L (275 mg/dL) Fluvastatin 20 mg/day baseline LDL‐C : 4.9 mmol/L (189 mg/dL) Fluvastatin 20 mg/day baseline HDL‐C : 1.2 mmol/L (46 mg/dL) Fluvastatin 20 mg/day baseline triglycerides: 2.1 mmol/L (186 mg/dL) Fluvastatin 40 mg/day baseline TC : 7.0 mmol/L (271 mg/dL) Fluvastatin 40 mg/day baseline LDL‐C : 4.8 mmol/L (186 mg/dL) Fluvastatin 40 mg/day baseline HDL‐C : 1.2 mmol/L (46 mg/dL) Fluvastatin 40 mg/day baseline triglycerides: 2.2 mmol/L (195 mg/dL)
Interventions	Lovastatin 10 mg/day for 6 weeks Lovastatin 20 mg/day for 6 weeks Lovastatin 40 mg/day for 6 weeks Fluvastatin 20 mg/day for 6 weeks Fluvastatin 40 mg/day for 6 weeks
Outcomes	per cent change from baseline at 6 weeks of serum TC, LDL‐C, HDL‐C, and triglycerides
Source of Funding	unknown
Notes	Lovastatin 10 mg/day for 6 weeks Lovastatin 20 mg/day for 6 weeks Lovastatin 40 mg/day for 6 weeks groups were not analysed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before and after design
Allocation concealment (selection bias)	High risk	Controlled before and after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐cholesterol	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAEs	High risk	No comparison possible
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding was not reported